Last Updated on December 24, 2023 by The Health Master
The United States Food and Drug Administration (USFDA) has given tentative approval to Lupin for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine tablets, 50 mg/25 mg, to market
Dolutegravir and Rilpivirine tablets, 50 mg/25 mg is a generic equivalent of Juluca tablets, 50 mg/25 mg of ViiV Healthcare, a statement from the company notified.
The tablets are used to treat HIV infections.
USFDA gives tentative approval for Levomilnacipran extended-release capsules
USFDA gives approval for Febuxostat tablets
USFDA gives approval for Prasugrel tablets
USFDA approves Fesoterodine Fumarate Extended-Release tablets
USFDA gives final approval for this Insomnia drug
USFDA approves this monoclonal antibody to treat multiple sclerosis
DCGI approves Covovax as booster dose
USFDA gives tentative approval for Levomilnacipran extended-release capsules
IPC includes dissolution test in IP: Read details
NPPA fixes retail price of 12 formulations: January 2023
Drug recall: Epinephrine API recalled due to this reason
Deadline for Medical Colleges to submit PG Admissions info: NMC
NPPA revised Retail Price of 93 scheduled formulations: January 2023
Tramadol: 3 Pharmaceutical Companies under scanner
NABL suspends accreditation of 80 laboratories
Latest Notifications regarding Pharmaceutical
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
